Citigroup’s Ascendis Pharma A/S ASND Stock Holding History

Citigroup’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.74M	Buy	+16,400	New	+$4.15M	﹤0.01%	2336
2026 Q2	–	Sell	-12,000	Closed	-$2.74M	–	5722
2026 Q1	$2.74M	Sell	12,000 -8,000	-40%	-$1.79M	﹤0.01%	2450
2025 Q4	$4.26M	Buy	+20,000	New	+$4.13M	﹤0.01%	2135
2024 Q4	–	Sell	-2,500	Closed	-$373K	–	5828
2024 Q3	$373K	Sell	2,500 -10,000	-80%	-$1.35M	﹤0.01%	3919
2024 Q2	$1.7M	Sell	12,500 -12,300	-50%	-$1.67M	﹤0.01%	2477
2024 Q1	$3.75M	Hold	24,800	–	–	﹤0.01%	1931
2023 Q4	$3.12M	Sell	24,800 -26,800	-52%	-$2.67M	﹤0.01%	1914
2023 Q3	$4.83M	Buy	51,600 +26,600	+106%	+$2.49M	﹤0.01%	1454
2023 Q2	$2.23M	Hold	25,000	–	–	﹤0.01%	2101
2023 Q1	$2.68M	Buy	25,000 +800	+3%	+$91.5K	﹤0.01%	1829
2022 Q4	$2.96M	Buy	+24,200	New	+$2.81M	﹤0.01%	1782

Other funds holding ASND

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return

Henry James International Management New York $330M AUM 35.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Citigroup's ASND Position: Q3 2026 in Review

Citigroup increased its Ascendis Pharma A/S (ASND) stake by 167% in Q3 2026, buying an estimated $12.1M and bringing the position to 76,508 shares worth $17.4M. The position accounts for 0.01% of the portfolio, ranked #1272.

Citigroup first reported a position in ASND in Q1 2015 and has held it in 36 quarters since. 99 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

Citigroup held 76,508 shares of Ascendis Pharma A/S worth $17.4M as of Q3 2026.
Citigroup bought 47,815 Ascendis Pharma A/S shares in Q3 2026, an estimated $12.1M.
Ascendis Pharma A/S made up 0.01% of Citigroup's portfolio in Q3 2026, its #1272 holding.
Citigroup first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 36 quarters since.
99 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.